Clinical validation of Endofaster� for a rapid diagnosis of Helicobacter pylori infection

Rodríguez, Eugenia Sánchez; Aldehuelo, Rubén Sánchez; León, Raquel Ríos; Mateos, Rosa María Martín; Paredes, Ana García García de; Argila, Carlos Martín de; Caminoa, Alejandra; Albillos, Agustı́n; Vázquez-Sequeiros, Enrique

doi:10.17235/reed.2019.6441/2019

Cited by 5 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lowest threshold provides slightly better sensitivity, at the expense of specificity, PPV, and NPV. These results are in accordance with previous studies 12…”

Section: Discussionsupporting

confidence: 94%

“…According to this ammonium concentration, HP was considered positive or negative. We have studied the diagnosis accuracy of EndoFaster using 2 different positive thresholds: ≥57 and >67 ppm/mL, in accordance with previous reports 12…”

Section: Methodsmentioning

confidence: 52%

“…During the endoscopy procedure, gastric juice was aspirated to carry out an automatic analysis by EndoFaster, as described previously. 12 This device aspirates 4 mL of gastric juice at the beginning of the endoscopic procedure and calculates the ammonium concentration. 13 According to this ammonium concentration, HP was considered positive or negative.…”

Section: Endoscopymentioning

confidence: 99%

See 2 more Smart Citations

Comparison Between Real-time Ammonium and pH Measurement, Immunohistochemistry, and Histochemistry for the Diagnosis of Helicobacter pylori

Carretero‐Barrio

Rodajo-Fernandez²,

Romio³

et al. 2021

Journal of Clinical Gastroenterology

Self Cite

View full text Add to dashboard Cite

Background: Helicobacter pylori (HP) infection has been implicated in several malignant and nonmalignant conditions. The confirmatory diagnosis of HP requires an endoscopic biopsy, followed by a rapid urease test, culture, and/or histopathologic examination using hemotoxylin and eosin, histochemical stains, or immunohistochemistry against HP. EndoFaster is a novel device that can perform real-time ammonium and pH measurements in gastric juice, allowing a diagnosis of HP during gastroduodenal endoscopy. Goal: This study aimed to validate the accuracy of EndoFaster and to compare different histochemical and immunohistochemical techniques for the diagnosis of HP infection. Study: Consecutive patients who underwent upper endoscopy at our center were prospectively enrolled. During the endoscopy procedure, gastric juice was aspirated to perform an automatic analysis by EndoFaster and gastric biopsies were taken. Histologic sections were reviewed to assess the histopathologic features. The sensitivity, specificity, positive predictive value, and negative predictive value were calculated for the EndoFaster test, Diff-Quick (DQ), and immunohistochemistry against HP (anti-HP) using Warthin-Starry as the gold standard for HP detection. Results: Overall, 80 patients were enrolled. In 19 cases (23,75%), histology was normal. In the remaining cases, varying degrees of inflammation were found. The sensitivity, specificity, positive predictive value, and negative predictive value were 73.33%, 86.00%, 75.86%, and 84.31% for the EndoFaster test using 67 ppm/mL as the positive threshold; 73.33%, 100%, 100%, and 86.21% for DQ; and 79.31%, 88.00%, 79.31%, and 88.00% for anti-HP, respectively. Conclusions: The EndoFaster test has good sensitivity and specificity for the diagnosis of HP during the gastroscopy procedure. DQ and anti-HP are excellent alternatives to Warthin-Starry for the detection of HP.

show abstract

“…The lowest threshold provides slightly better sensitivity, at the expense of specificity, PPV, and NPV. These results are in accordance with previous studies 12…”

Section: Discussionsupporting

confidence: 94%

Section: Methodsmentioning

confidence: 52%

Section: Endoscopymentioning

confidence: 99%

See 1 more Smart Citation

Comparison Between Real-time Ammonium and pH Measurement, Immunohistochemistry, and Histochemistry for the Diagnosis of Helicobacter pylori

Carretero‐Barrio

Rodajo-Fernandez²,

Romio³

et al. 2021

Journal of Clinical Gastroenterology

Self Cite

View full text Add to dashboard Cite

show abstract

“…EndoFaster (NISO Biomed S.r.l., Turin, Italy) was first introduced in 2005. EndoFaster is a real-time analysis machine using gastric juice that provides information on ammonium concentration and gastric pH (Sánchez Rodríguez et al, 2020). Because H. pylori can produce the urease enzyme, which breaks down urea into carbon dioxide and ammonia, this machine could diagnose H. pylori infection through a urease test on gastric juice.…”

Section: New Innovative Tool (Endofaster)mentioning

confidence: 99%

Endoscopic Diagnosis for H. pylori Infection: White Light Imaging (WLI) vs. Image-Enhanced Endoscopy (IEE)

Chatrangsun

Vilaichone

2021

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

infection. However, each technique has some limitations. For example, patients who use proton pump inhibitor PPI), antibiotics, anti-platelet, anti-coagulant, or direct oral anti-coagulant (DOAC) medications. Real-time endoscopy along with conventional white light imaging WLI) and image-enhanced endoscopic (IEE) techniques, such as narrow-band imaging (NBI), linked color imaging (LCI) and blue laser imaging (BLI), appear to have important roles in clinical practice to identify H. pylori-infected status (Malfertheiner et al., 2007). This article aimed to review the endoscopic diagnostic options and findings for H. pylori infection. Current diagnostic tests for H. pylori infectionMany diagnostic tests are available, including invasive

show abstract

“…Previous studies have reported that the occurrence of the majority of gastric carcinoma cases were the result of the combined action of multiple environmental factors, such as dietary, lifestyle and environmental influential factors, and tumor susceptibility factors, such as the influencing factors of blood vessel invasion (6,7). It was previously identified that gastric carcinoma caused by Helicobacter pylori was closely associated with the immune response of the body (8,9). Moreover, cellular immunity dominated by cytokines was discovered to be involved in the occurrence of gastric carcinoma (10)(11)(12).…”

Section: Introductionmentioning

confidence: 99%

Apatinib inhibits gastric carcinoma development by regulating the expression levels of IL‑17 via the Bax/Bcl‑2 signaling pathway

2021

View full text Add to dashboard Cite

Gastric carcinoma is a common type of gastrointestinal tumor with high morbidity and mortality rates. IL-17 is a newly discovered cytokine that has been reported to serve an important role in the development of gastric carcinoma. The potential effect of apatinib on IL-17 expression levels in the development of gastric carcinoma has been rarely reported. The present study aimed to investigate the potential mechanism of IL-17 and apatinib in the development of gastric carcinoma. A total of 30 tumor and para-carcinoma tissues were collected from 30 patients with gastric carcinoma between January 2019 and December 2019 and the expression levels of IL-17 in the tissues were analyzed by reverse transcription-quantitative PCR and western blotting. An in vitro model of gastric carcinoma was also established using the HGC-27 cell line, in which the cells were divided into control, IL-17, IL-17-apatinib and apatinib groups. The expression levels of IL-17, Bax, Bcl-2 and caspase-3 were analyzed using reverse transcription-quantitative PCR and western blotting. An MTT assay and flow cytometry were used to analyze the proliferation and apoptosis of HGC-27 cells, respectively, and a Transwell assay was used to analyze the invasive ability of HGC-27 cells. The results revealed that the expression levels of IL-17 were significantly upregulated in the gastric carcinoma tissues compared with the para-carcinoma tissues. In vitro, IL-17 treatment promoted the proliferation and invasive ability of HGC-27 cells, but inhibited the apoptosis with the significantly downregulated expression levels of Bax and caspase-3 and the upregulated expression levels of Bcl-2 than control group. Conversely, apatinib treatment significantly inhibited the proliferative and invasive abilities of HGC-27 cells, but promoted cell apoptosis in the IL-17 and IL-17-apatinib groups.. Collectively, the present results suggested that the upregulation of IL-17 may be associated with the occurrence and development of gastric carcinoma. The findings indicated that apatinib may inhibit gastric carcinoma development by regulating IL-17 expression via the Bax/Bcl-2 signaling pathway. Therefore, the present findings may enhance the current knowledge of the effect of apatinib on gastric carcinoma cells.

show abstract

Clinical validation of Endofaster� for a rapid diagnosis of Helicobacter pylori infection

Cited by 5 publications

References 11 publications

Comparison Between Real-time Ammonium and pH Measurement, Immunohistochemistry, and Histochemistry for the Diagnosis of Helicobacter pylori

Comparison Between Real-time Ammonium and pH Measurement, Immunohistochemistry, and Histochemistry for the Diagnosis of Helicobacter pylori

Endoscopic Diagnosis for H. pylori Infection: White Light Imaging (WLI) vs. Image-Enhanced Endoscopy (IEE)

Apatinib inhibits gastric carcinoma development by regulating the expression levels of IL‑17 via the Bax/Bcl‑2 signaling pathway

Contact Info

Product

Resources

About